

O I P E
APR 02 2004

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/623,464
Filing Date	July 18, 2003
First Named Inventor	Deh-Ming Chang
Group Art Unit	1645
Examiner Name	Unassigned
Total Number of Pages in This Submission	411-000100US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> USPTO Form 1449; Cited References (50); receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Paul Littlepage, Reg. No. 48,581, Quine Intellectual Property Law Group, P.C.
Signature	
Date	March 31, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Amelia Weintraub
Signature	
Date	March 31, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450, on March 31, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By A. Weintraub
Amelia Weintraub

Attorney Docket No. 411-000100US
Client Ref. No. G85

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Deh-Ming Chang, et al.

Examiner: Unassigned

Application No.: 10/623,464

Art Unit: 1645

Filed: July 18, 2003

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

For: MODULATION OF INTERLEUKIN-
10 BY DHEA
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Paul Littlepage
Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A-B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>APR 02 2004 (use as many sheets as necessary)</p> <p>PATENT & TRADEMARK OFFICE</p>		Complete if Known		
		Application Number		10/623,464
		Filing Date		July 18, 2003
		First Named Inventor		Deh-Ming Chang
		Group Art Unit		1645
		Examiner Name		Unassigned
		Attorney Docket Number		411-000100US
Date Submitted		March 31, 2004		

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
01	4,366,241			Tom et al.	12-28-1982
02	4,376,110			David et al.	03-08-1983
03	4,517,288			Giegel et al.	05-14-1985
04	4,837,168			de Jaeger et al.	06-06-1989
05	6,552,010	B1		Schwartz et al.	04-22-2003
06	6,605,591	B1		Schwartz	08-12-2003

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	07	WO	00/54763	A2	Genelabs Technologies, Inc.	09-21-2000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	08	al-Janadi, et al., <u>J. Clin. Immunol.</u> , 1993(13):58-67.				
	09	Anaya, et al., <u>J. Rheuma.</u> , 2002, 29(9):1874-1876.				
	10	Araghi-Niknam, et al., <u>Proc. Soc. Exp. Biol. Med.</u> , 1997, 216:386-91.				
	11	Badou, et al., <u>J. Virology</u> , 2000, 74(22):10551-10562.				
	12	Bombardier, et al., <u>Arthritis Rheum.</u> , 1992, 35:630-40.				
	13	Chang, et al., <u>Arthritis Rheum.</u> , 2002, 46(11):2924-27.				
	14	Cortes, et al., <u>Blood</u> , 1995, 85(9):2516-2520.				
	15	Daynes, et al., <u>Eur. J. Immunol.</u> , 1990, 20:793-802.				
	16	Ebeling, et al., <u>Lancet</u> , 1994 (343):1479-81.				
	17	Fayad, et al., <u>Blood</u> , 2001, 97(1):256-263.				
	18	Gordon, et al., <u>Cytokine</u> , 2001, 16(5):178-86.				
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/623,464
		Filing Date	July 18, 2003
		First Named Inventor	Deh-Ming Chang
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	411-000100US
		Date Submitted	March 31, 2004

19	Hagiwara, et al., <u>Arthritis Rheum.</u> , 1996, 39:379-385.
20	Handwerger, et al., <u>Springer Semin. Immunopathol.</u> , 1994, 16:153-80.
21	Houssiau, et al., <u>Lupus</u> , 1995, 4:393-395.
22	Isomäki, et al., <u>Arthritis Rheum.</u> , 1996, 39(3):386-395.
23	Labrie, et al., <u>Ann. N.Y. Acad. Sci.</u> , 1995, (774):16-28.
24	Lacki, et al., <u>Clinical Rheumatology</u> , 1997, 16(3):275-278.
25	Liang, et al., <u>Arthritis Rheum.</u> , 1989, 32:1107-18.
26	Linker-Israeli, et al., <u>J. Immunol.</u> , 1991, 147:117-23.
27	Llorente, et al., <u>Eur. Cytokine Netw.</u> , 1993, 4:421-30.
28	Llorente, et al., <u>Arthritis Rheum.</u> , 1994, 37(11):1647-1655.
29	Llorente, et al., <u>Arthritis Rheum.</u> , 2000, 43(8):1790-1800.
30	Lucas, et al., <u>J. Clin. Invest.</u> , 1985, 75:2091-93.
31	Mease, et al., <u>Arthritis Rheum.</u> , 2000, 43(Suppl. 1):S271.
32	Melez, et al., <u>Arthritis Rheum.</u> , 1980, 23:41-7.
33	Mund, et al., <u>JAMA</u> , 1963, 183:917-20.
34	Nunnari, et al., <u>Ann. Intern. Med.</u> , 2003, 139(1):26-30.
35	Park, et al., <u>Clin. Exp. Rheumatol.</u> , 1998, 16(3):283-8.
36	Parker, <u>Endocrinol. Metab. Clin. North Am.</u> , 1991 20:401-21.
37	Perrier, et al., <u>J. Rheumatol.</u> , 2000, 27:935-9.
38	Petri, et al., <u>Arthritis Rheum.</u> , 2002 (46):1820-9.
39	Petri, et al., <u>Rheumatology</u> , 2003:42(Suppl. 1):19.
40	Petri, et al., <u>Arthritis Rheum.</u> 1991, 34:1538-45.
41	Richaud-Patin, et al., <u>Rev. Invest. Clin.</u> , 1995, 47:267-72.
42	Roubinian, et al., <u>Arthritis Rheum.</u> , 1979, 22:1162-69.
43	Straub, et al., <u>J. Clin. Endocrinol. Metab.</u> , 1998, 83:2012-17.
44	Suzuki, et al., <u>Clin. Immunol. Immunopathol.</u> , 1991, 61:202-11.
45	Tabata, et al., <u>Arch. Dermatol. Res.</u> , 1997, 289:410-14.
46	Takemura, et al., <u>Virchows Archiv.</u> , 1994(424):459-64.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>		Application Number	10/623,464
		Filing Date	July 18, 2003
		First Named Inventor	Deh-Ming Chang
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	411-000100US
		Date Submitted	March 31, 2004

	47	Tan, et al., <u>Arthritis Rheum.</u> , 1982, 25:1271-77.	
	48	van Vollenhoven, et al., <u>Arthritis Rheum.</u> , 1994(37):1305-10.	
	49	van Vollenhoven, et al., <u>Arthritis Rheum.</u> , 1995(38):1826-31.	
	50	Zietz, et al., <u>J. Rheumatol.</u> , 2000, 27:911-8.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.